2'-deoxy-2'-methylenecytidine has been researched along with icrf 193 in 1 studies
| Studies (2'-deoxy-2'-methylenecytidine) | Trials (2'-deoxy-2'-methylenecytidine) | Recent Studies (post-2010) (2'-deoxy-2'-methylenecytidine) | Studies (icrf 193) | Trials (icrf 193) | Recent Studies (post-2010) (icrf 193) |
|---|---|---|---|---|---|
| 30 | 2 | 0 | 155 | 0 | 30 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
1 other study(ies) available for 2'-deoxy-2'-methylenecytidine and icrf 193
| Article | Year |
|---|---|
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |